

CADTH Scoping Summary

A Condition-Level Review on Post–COVID-19 Condition (Long COVID)

Version: 1.0

Publication Date: September 2021

Report Length: 8 Pages

Authors: Sinwan Basharat, Sarah McGill

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to Requests@CADTH.ca

Purpose of This Document

This document describes the preliminary scoping and rationale for a condition-level review on the topic of post–COVID-19 condition, also known as long COVID. A condition-level review is an assessment of the evidence on a range of health technologies and emerging issues on all aspects of a condition, including prevention, identification, treatment, and management. As part of the scoping process, CADTH is consulting with jurisdictions across Canada, together with experts and stakeholders who are leading different research initiatives, clinical programs, and health systems planning related to post–COVID-19.

This scoping summary is not based on the findings of a systematic search but rather provides an overview about the evidence and emerging research questions that can help frame the development of a condition-level review. It also outlines published or preprint evidence resources that provide additional context about the condition and a preliminary assessment about potential evidence gaps that could be relevant for health systems in Canada.

Background

What Is Post–COVID-19 or Long COVID?

As health authorities in Canada and across the world continue efforts to help control the spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), there is growing concern that a subset of people with COVID-19 may not adequately recover from initial phases of the infection and could experience long-term effects for weeks and months. Post–COVID-19 condition, commonly referred to as long COVID (among many other terms being used), is a new condition recognized by the Public Health Agency of Canada (PHAC) and the World Health Organization (WHO). The condition affects some people following the acute phase of COVID-19 and could potentially affect hundreds of thousands of people in Canada and millions of people worldwide.^{1,2} A patient-led movement was launched in 2020 to raise awareness about post–COVID-19 condition and those affected with it continue to advocate for its recognition, as it is not given similar attention as acute COVID-19.³

The National Institute for Health and Care Excellence (NICE) and the Centers for Disease Control and Prevention (CDC) define post–COVID-19 condition as a diverse illness or possibly a set of multiple illnesses, whereby people experience new or persisting symptoms for several weeks or months after being initially infected with SARS CoV-2. The differentiation between acute phases of COVID-19 and post–COVID-19 condition varies with each organization and has been defined as occurring either 4 weeks⁴ or 12 weeks⁵ after the initial infection. However, a positive COVID-19 molecular test is not necessary for a potential diagnosis of post–COVID-19 condition, as testing may not be available to all people at the time of initial infection.⁵ Post–COVID-19 condition may affect different organ systems including pulmonary, cardiovascular, neurological, and musculoskeletal systems, among others.^{5,6} Symptoms also vary widely, but the most frequently reported symptoms are fatigue, body aches, respiratory difficulties such as shortness of breath, and cognitive and mental health challenges.^{7,8} The condition may have severe effects on people's well-being and quality of life, and the relatively high number of people who could be affected will have important implications for health systems.^{3,6}

Prevalence

Owing to a lack of standardized diagnostic criteria, varied study designs, and inclusion criteria (e.g., some studies consider people hospitalized with COVID-19, whereas others include anyone suspected of having had COVID-19), there is substantial variability in prevalence estimates. Two systematic reviews report that between 63%⁹ and 83%⁷ of people with a confirmed diagnosis of COVID-19 may experience new or persisting symptoms after 4 weeks of their initial diagnosis. These systematic reviews also report that 56%⁷ and 46%⁹ of people continue to experience symptoms after 12 weeks and 90 days, respectively. One study reports that after 6 months, 26%¹⁰ of people may continue to experience symptoms. A COVID-19 infection survey in the UK showed that 13.7% of people with a positive COVID-19 test self-reported experiencing symptoms for 12 weeks or longer.¹¹ Based on the lower prevalence estimates, with more than 1.4 million¹² people in Canada testing positive for the infection, potentially more than 140,000 to 190,000 people may have or develop post-COVID-19 condition in the future.

Risk Factors

People of all ages, from all demographic backgrounds, and with pre-existing health conditions can be affected by post-COVID-19.^{3,6} However, evidence from cohort studies suggest that people who experience more symptoms during the acute phase of the infection and people with certain comorbidities (such as hypertension or obesity) may be more likely to develop the condition.^{13,14} One systematic review has reported that age, sex, and hospitalization may be associated with a higher risk of developing persistent symptoms following the acute phase of COVID-19.¹⁵ Although there is relatively less research examining the experiences of children, they can also develop post-COVID-19; some may even develop specific pediatric subtypes that may resemble other inflammatory diseases.^{16,17} The long-term effects of COVID-19, whether the effect is a new condition or an exacerbation of existing health issues, may increase the risk of developing other health conditions. Emerging evidence from 1 cohort study reported that people who contracted the virus but were not hospitalized were more likely to develop pulmonary, neurological, metabolic, and cardiovascular conditions in the 6 months following the infection compared to similar people within the same health care database who did not get infected.¹⁸ These emerging findings suggest that post-COVID-19 may affect a wide range of people and, given the diagnostic uncertainty and varied symptoms, this could increase the demand on many different health services. Further research is needed to analyze individual risk factors for developing post-COVID-19 condition and understand if and how the condition may be associated with other health concerns.

Published Evidence Reviews

Preliminary scoping of the published literature has identified a wide range of published studies, preprint papers, and grey literature reports about post-COVID-19. These reports help better understand various aspects of post-COVID-19 condition and to frame questions that could be included in the condition-level review. Following, we describe highlights (i.e., not a comprehensive list of literature identified to date) of some of the published evidence reviews that could be relevant for health care decision-makers in Canada to help frame the emerging evidence needs. Some questions that have emerged from these published reviews or have been developed based on our scoping work to date are shown in Table 1.

Disease Classification

Several systematic reviews describe the different types, length, and prevalence of symptoms associated with post–COVID-19.⁷⁻⁹ However, these reviews have noted that, given that the condition is not well-classified, there is a need for higher-quality methodological studies that use standardized case definitions and more studies measuring long-term outcomes (beyond 12 weeks).^{7,8} The [CANCOV study](#) ongoing across 4 provinces in Canada will add to the evidence base about long-term outcomes (1 year after initial hospitalization) of people with COVID-19 and the impact on their caregivers. WHO is convening a multidisciplinary panel to develop a clinical or case definition of post–COVID-19; however, at the time of this report, there is no consensus available on its clinical classification.¹⁹

A [scoping review](#) reported that 120 peer-reviewed studies on post–COVID-19 were published by January 2021. Of these, 49.1% of the studies were focused on the signs and symptoms of the condition and 10.8% of the studies were focused on understanding the pathophysiology — the bodily processes associated with a disease — of the condition.²⁰ Emerging research and systematic reviews are aiming to better understand the condition's pathophysiology, risk factors, varied presentation in different people (including children), and possible preventive interventions.^{3,21}

Clinical Guidance

Jointly with UK-based clinical networks, NICE published [rapid guidelines](#) for identifying, assessing, and managing the long-term effects of COVID-19, including identifying and treating people with post–COVID-19.⁵ These guidelines were developed for front-line health care professionals working in primary and community-level care. CDC produced a similar [interim guidance](#) for health care providers to support people with post–COVID-19 condition (may include multiple conditions).²²

Within Canada, Alberta Health Services produced a [rapid evidence report](#) detailing guidance for health care professionals about the treatment and management of post–COVID-19 and its associated symptoms.²³ An additional report describes a [rehabilitation response framework](#) for the condition.²⁴ Institut national d'excellence en santé et services sociaux (INESSS) produced a [management support tool](#) for front-line health care professionals.²⁵ Emerging research examining the effectiveness of different preventive, rehabilitation, and treatment interventions will help inform clinical guidance. CADTH is also collaborating with PHAC and the Alberta Research Centre for Health Evidence (ARCHE) on a [systematic review](#) assessing risk factors and preventive interventions for post–COVID-19 condition.²⁶

Review of Care Models

Ontario's Evidence Synthesis Network produced a [briefing note](#) describing the various program features, development, and governance structures of emerging long COVID clinics or specialized recovery clinics for people with post–COVID-19.²⁷ The report identified clinics operating in Canada, the US, the UK, and Italy, with different inclusion criteria, services, and funding structures.

A [rapid systematic review](#) by COVID-END and the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance identified 12 studies describing different care models for treating

post-COVID-19 condition or long COVID such as specialized recovery clinics and care delivered through primary care.²⁸ Limited information about the effectiveness of care models was identified in the review but will be important for emerging research to explore as interventions begin to collect and report outcomes. In particular, the effectiveness of different models of care and their impact on health systems will be important to examine, as the condition may put increased demands on primary care.^{2,6}

Table 1: Potential Research Questions That Could Be Included in the Condition-Level Review

Condition-level review area	Questions
Scoping	<p>What is the research landscape about post-COVID-19 condition in terms of evidence gaps, concepts, context, and volume of research literature?</p> <p><i>A scoping review is being conducted by CADTH.</i></p>
Prevention	<p>What are risk factors for developing post-COVID-19 condition after a SARS CoV-2 infection?</p> <p>What is the clinical effectiveness of different interventions to prevent post-COVID-19 condition?</p> <p>What is the cost-effectiveness of different interventions to prevent post-COVID-19 condition?</p>
Classification and diagnosis	<p>What are the policy and clinical practice implications of post-COVID-19 in children?</p> <p>What are the diagnostic criteria for post-COVID-19 condition and its subtypes?</p> <p>What tools and strategies are being used in Canada and other similar countries to identify people who may have developed post-COVID-19?</p>
Treatment and/or management	<p>What is the clinical effectiveness of different pharmaceutical and rehabilitation therapies for treating post-COVID-19?</p> <p>What is the clinical effectiveness of vaccines to treat post-COVID-19?</p> <p>What is the evidence on different models of care being implemented in Canada and across the world?</p> <p>What are the policy, practice, and budget impact implications on health systems due to post-COVID-19 condition?</p>

SARS = severe acute respiratory syndrome coronavirus 2.

Rationale for Condition-Level Review

CADTH’s Implementation Support and Knowledge Mobilization team received early indications from various jurisdictions that addressing the needs of people and health systems for post-COVID-19 condition is a growing concern. Because post-COVID-19 condition or long COVID is not very well-understood, there is little consensus about different aspects of the condition and evidence is rapidly evolving. There are uncertainties about the number of people who have or could develop the condition in Canada, the risk factors for developing the condition, the effectiveness of interventions and health technologies that can support people in their recoveries, and the impact the condition may have on people and health systems.

As research continues to evolve, CADTH’s condition-level review aims to inform health care decision-makers in Canada about the appropriate use of health technologies and interventions to support the prevention, clinical classification, diagnosis, treatment, and management of post-COVID-19 condition. Through this comprehensive lens on all aspects

of the condition, the review aims to support health systems to use the latest research to guide their planning and delivery of services. CADTH's Implementation Support and Knowledge Mobilization team is currently assessing and engaging with health care decision-makers across Canada to understand specific evidence needs, which, together with input from CADTH's Devices Advisory Committee, will guide final decisions of which evidence will be reviewed as part of the condition-level review. A systematic scoping review is also ongoing by CADTH to better understand evidence gaps.

Equipping health systems to address the needs of people with post-COVID-19 condition will require using the best available evidence. Amid the complexity and rapidly changing evidence base, the condition-level review will provide an accessible platform for health technology reviews, rapid response reports, evidence reviews, and recommendations — including those produced by other health technology assessment and evidence synthesis organizations — to inform jurisdictions across Canada.

If you have questions about the scoping of the condition-level review on post-COVID-19 or would like to be involved in helping shape its development, please reach out to a CADTH Liaison Officer in your jurisdiction.

References

1. Public Health Agency of Canada. Statement from the Chief Public Health Officer of Canada on July 7, 2021. Ottawa (ON): Government of Canada; 2021: <https://www.canada.ca/en/public-health/news/2021/07/statement-from-the-chief-public-health-officer-of-canada-on-july-7-2021.html>. Accessed 2021 Sep 1.
2. Rajan S, Khunti K, Alwan N, et al. In the wake of the pandemic: preparing for Long COVID. (*European Observatory Policy Brief 39*). Copenhagen (Denmark): European Observatory on Health Systems and Policies; WHO; 2021: <https://www.euro.who.int/en/about-us/partners/observatory-old/publications/policy-briefs-and-summaries/in-the-wake-of-the-pandemic-preparing-for-long-covid-2021>. Accessed 2021 Sep 1.
3. Alwan NA. The road to addressing Long Covid. *Science*. 2021;373(6554):491-493.
4. Centers for Disease Control and Prevention. Post-COVID conditions. 2021; <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html>. Accessed 2021 Sep 1.
5. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. (*NICE guideline NG188*) 2020; <https://www.nice.org.uk/guidance/NG188>. Accessed 2021 Sep 1.
6. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020;370:m3026.
7. Domingo FR, Waddell LA, Cheung AM, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: a living systematic review [non peer-reviewed preprint]. *medRxiv*. 2021. <https://doi.org/10.1101/2021.06.03.21258317>.
8. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2021;11(1):16144.
9. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. *Eur J Intern Med*. 2021 Jun 15.
10. Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. *PLoS One*. 2021;16(7):e0254523.
11. Office for National Statistics (UK). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. 2021; <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>. Accessed 2021 Aug 18.
12. Public Health Agency of Canada. COVID-19 daily epidemiology update. Updated: August 11, 2021. 2021; <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>. Accessed 2021 Aug 12.
13. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med*. 2021;27(4):626-631.
14. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ*. 2021;374:n1648.
15. Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. *Int J Clin Pract*. 2021:e14357.
16. Evans C, Davies P. SARS-CoV-2 paediatric inflammatory syndrome. *Paediatr Child Health (Oxford)*. 2021;31(3):110-115.
17. Public Health Ontario. Pediatric post-acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C): what we know so far. Toronto: Public Health Ontario; 2021: <https://www.publichealthontario.ca/-/media/documents/ncov/covid-wwksf/2021/05/wwksf-children-long-term-sequelae.pdf?la=en>. Accessed 2021 Sep 1.
18. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-264.
19. Diaz JV, Soriano JB. A Delphi consensus to advance on a Clinical Case Definition for Post COVID-19 condition: A WHO protocol [non peer-reviewed preprint]. *Protocol Exchange*. 2021. <https://doi.org/10.21203/rs.3.pex-1480/v1>. Accessed 2021 Sep 1.
20. Akbarialiabad H, Taghrir MH, Abdollahi A, et al. Long COVID, a comprehensive systematic scoping review. *Infection*. 2021 Jul 28:1-24.
21. World Health Organization (WHO). Expanding our understanding of post COVID-19 condition. Report of a WHO webinar, 9 February 2021. Geneva (Switzerland): WHO; 2021: <https://www.who.int/publications-detail-redirect/9789240025035>. Accessed 2021 Aug 12.
22. Centers for Disease Control and Prevention. Evaluating and caring for patients with post-COVID conditions: interim guidance. 2021; <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html>. Accessed 2021 Aug 12.
23. Alberta Health Services. What is known about the optimal management for patients with post-COVID conditions or complications occurring after acute COVID-19 infection? *COVID-19 Scientific Advisory Group Rapid Evidence Report*. 2021. <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-rapid-review-management-post-covid-conditions.pdf>. Accessed August 12, 2021.
24. Alberta Health Services. Post COVID-19 rehabilitation response framework summary report. 2021. <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-post-covid-rehab-response-framework-summary.pdf>. Accessed 2021 Aug 12.
25. INESSS. Management Support Tool for Post COVID-19 Conditions (English). 2021. https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_INESSS_Management_support_tool_post_COVID.pdf. Accessed 2021 Aug 12.

26. Pillay J, Hartling L, Wingert A, et al. Protocol for systematic reviews on risk factors and preventive interventions for post Covid-19 condition. University of Alberta ARCHE Dataverse2021: <https://dataverse.library.ualberta.ca/dataset.xhtml?persistentId=doi:10.7939/DVN/FSRCEU>. Accessed 2021 Sep 1.
27. Long COVID-19 clinics. (*Evidence Synthesis Network briefing note*): Ontario Ministry of Health, Research, Analysis, and Evaluation Branch; 2021 Apr 27: <https://esnetwork.ca/briefings/long-covid-19-clinics/>. Accessed 2021 Sep 1.
28. Decary S, Dugas M, Stefan T, et al. Care models for long COVID - a rapid systematic review. Toronto: SPOR Evidence Alliance, COVID-END Network; 2021: https://sporevidencealliance.ca/wp-content/uploads/2021/06/Care-Models-for-Long-COVID_Full-Report_2021.06.18.pdf. Accessed 2021 Aug 8.